Cuorips (4894) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Revenue increased substantially due to the ramp-up in sales from the regenerative medicine products business; however, the operating loss widened due to upfront investments in research and development and the establishment of the business infrastructure. Revenue amounted to ¥2.1B (+674.2% YoY), Operating Income was ¥-7.7B (a wider loss compared with ¥-5.6B in the previous year), Ordinary Income was ¥-7.3B, and Net Income was ¥-7.4B. The increase in revenue was largely attributable to a rebound from the extremely low base in the previous year, while a 69.1% increase in R&D expenses was the primary factor behind the wider loss.

Factors Affecting Results

【Revenue】Revenue increased 674.2% to ¥2.1B from ¥0.3B in the same period of the previous year. As the Company operates as a single segment—the regenerative medicine products business—no breakdown by business is disclosed; however, the main driver of the revenue increase was the recognition of sales during the business ramp-up phase. Progress against the full-year forecast of ¥2.1B was 97.6%, a high level, with nearly the entire full-year plan recognized by Q3.

【Profit and Loss】Gross profit was ¥1.3B, and the gross margin declined to 61.0% from 83.2% in the same period of the previous year. SG&A expenses amounted to ¥9.0B (+53.1% YoY), with R&D expenses of ¥4.5B (+69.1% YoY) representing the primary source of the increase. The operating loss widened to ¥7.7B from ¥5.6B in the previous year, resulting in an operating margin of -372.5%. The ordinary loss was ¥7.3B, partially offset by ¥0.4B in non-operating income, mainly interest income and foreign exchange gains. The net loss was ¥7.4B (¥7.3B attributable to owners of the parent), representing a wider loss YoY. The results reflect higher revenue but lower earnings, namely a wider loss.

Segment Analysis

As the Company operates as a single segment, the regenerative medicine products business, no segment-level disclosure is provided.

Key Financial Indicators

【Profitability】The operating margin was -372.5% and the net profit margin was -356.2%, both representing substantial loss levels and reflecting an expense structure characterized by upfront development investment, with R&D expenses reaching 215.4% of revenue. The gross margin declined to 61.0% from 83.2% in the same period of the previous year.【Cash Flow Quality】R&D expenses of ¥4.5B accounted for approximately 60% of the ¥7.4B net loss, indicating that development investment was the primary cause of the loss. Accounts receivable were very small relative to total assets, indicating that the increase in revenue was not accompanied by an accumulation of trade receivables.【Investment Efficiency】Annualized ROE was -19.5% and annualized ROIC was -70.5%, indicating that invested capital has not yet reached the stage of generating business profits.【Financial Soundness】The equity ratio was 96.5%, the current ratio exceeded 3,705.8%, and the debt-to-equity ratio was 0.04x, indicating an extremely conservative financial foundation and high resilience in short-term liquidity management. Cash and deposits amounted to ¥35.7B, accounting for 68.5% of total assets.

Cash Flow Analysis

Cash and deposits remained high at ¥35.7B; however, they decreased by ¥10.2B from ¥45.9B in the same period of the previous year, as ongoing operating losses and funding for R&D and business operations reduced the balance. R&D expenses of ¥4.5B accounted for approximately 60% of the ¥7.4B net loss, indicating that development investment was the primary source of cash consumption. While inventories decreased 32.4% YoY to ¥0.3B, annualized DIO remained high at 104 days, leaving room for improvement in inventory turnover efficiency relative to cost of sales. Current assets of ¥46.4B substantially exceeded current liabilities of ¥1.3B, limiting concerns regarding short-term liquidity.

Earnings Quality

Non-operating income of ¥0.4B consisted primarily of ¥0.1B in interest income and ¥0.1B in foreign exchange gains; it should be noted that both were temporary and non-recurring factors unrelated to the core business. These non-operating income items were equivalent to 17.9% of revenue and contributed to reducing the ordinary loss relative to the operating loss. No extraordinary profit or loss items were identified. Comprehensive income was ¥-7.7B, and the difference from the ¥-7.3B net loss attributable to owners of the parent was due to foreign currency translation adjustments of ¥-0.3B; the difference was not material. Retained earnings deteriorated to ¥-34.8B from ¥-27.5B in the same period of the previous year, indicating an accumulation of losses consistent with the net loss for the period.

Earnings Forecast and Guidance

The full-year earnings forecast was revised during the current quarter. Against the full-year revenue forecast of ¥2.1B, cumulative Q3 revenue was ¥2.1B, representing progress of 97.6% and substantially exceeding the standard Q3 progress level of 75%. Against the full-year operating loss forecast of ¥10.2B, the cumulative Q3 operating loss was ¥7.7B, representing progress of 75.3%; against the full-year net loss forecast of ¥9.8B, the cumulative Q3 net loss was in the ¥7.3B range, representing progress of 74.5%. Both were broadly in line with standard progress levels. Nearly the entire revenue plan had been recognized by Q3, indicating a high likelihood of achieving the full-year revenue target, while loss progress remained at a standard level.

Shareholder Returns

The Q2 dividend was ¥0 per share, and the full-year dividend forecast was also ¥0, with no revision to the dividend forecast. As the Company recorded a net loss attributable to owners of the parent, there is currently no basis for calculating a payout ratio involving cash dividends. The no-dividend policy is consistent with the Company’s current business stage, in which its ¥35.7B in cash and deposits is being prioritized for R&D and commercialization. No share repurchases were identified.

Risk Factors

1. Development, approval, and commercialization delay risk: R&D expenses were ¥4.5B against revenue of ¥2.1B, while the operating loss was ¥7.7B. Delays in commercialization could extend the period of continued losses.

2. Ongoing capital consumption risk: Retained earnings deteriorated by ¥7.3B YoY to ¥-34.8B, while cash and deposits decreased by ¥10.2B YoY. If revenue growth is unable to sufficiently absorb the increase in expenses, the need for future financing may increase.

3. Inventory turnover and quality control risk: Annualized DIO was 104 days, exceeding the generally monitored threshold of 90 days. Regenerative medicine products are subject to significant quality-control and expiration-date constraints, and misalignment with sales and production plans could increase the risk of inventory write-downs.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

Among development-stage companies in the same industry, both the operating margin and net profit margin are substantially below the median.

Growth and Capital Efficiency

The revenue growth rate substantially exceeds the industry median, but this largely reflects a rebound from the low level of the previous year’s results.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Revenue increased 674.2% YoY to ¥2.1B, with progress against the full-year forecast at a high 97.6%; however, the operating loss widened YoY, indicating that the increase in revenue has not been sufficient to absorb upfront investments centered on R&D expenses.

2. The financial foundation, comprising ¥35.7B in cash and deposits, a current ratio exceeding 3,705.8%, and a debt-to-equity ratio of 0.04x, supports short-term liquidity and financial flexibility.

3. Annualized DIO of 104 days, annualized ROIC of -70.5%, and an operating margin of -372.5% are indicators that warrant ongoing monitoring of commercialization progress, inventory efficiency, and the recovery of invested capital.

Theoretical Share Price (Reference Value)

Sensitivity: ¥218–¥230 at ±1% for the cost of equity, and ¥216–¥229 at ±0.1 for ω.

Notes:

• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-08 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---